Compare Halliburton Company (HAL) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halliburton Company vs Viatris Inc — how do they compare? Halliburton Company trades at $33.57 (market cap $28.16B), while Viatris Inc trades at $16.25 (market cap $18.69B). The key difference: Halliburton Company is the larger of the two by market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| HAL | VTRS | |
|---|---|---|
Market Cap | $28.16B | $18.69B |
Sector | Energy | Health |
52-Week High | $42.98 | $17.86 |
52-Week Low | $20.97 | $9.49 |
Enterprise Value | $34.31B | $30.80B |
Dividend Yield | 2.01% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Halliburton (HAL) trades at $33.64, up 5.49% on the day, with a bullish technical signal despite a near-term overbought RSI. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Recent contract wins in international markets, such as with Kuwait Oil Company and Beetaloo Energy, highlight growth initiatives, though net income declined in 2025. The stock's valuation appears reasonable with a P/E of 17.7 and P/S of 1.27.
The outlook is supported by strong analyst sentiment with a $43.60 price target, but risks include geopolitical tensions impacting Middle East operations and a softer oilfield services market. Earnings growth from international expansion is the key catalyst, while margin pressure and debt levels warrant monitoring for sustained shareholder value.
Viatris (VTRS) trades at $16.28, down 0.91% on the day, with a bearish technical signal and mixed fundamentals. The company reported a net loss of $3.51 billion in 2025 despite recent quarterly earnings beats, including Q2 2026 EPS of $0.69 versus $0.62 expected. Revenue declined to $14.30 billion in 2025, but operational cash flow remains strong at $2.32 billion. Recent news highlights divestitures and FDA approval for Gwyn Lo, a contraceptive patch.
Outlook is cautious due to persistent losses and high P/E of 236.2, but dividend payments and cost-cutting efforts offer stability. Risks include competitive pressures and debt levels, while analyst consensus leans hold. The stock's value hinges on margin improvement and debt reduction progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
